The effect of rFVIIa on pro- and anti-inflamatory cytokines in serum and cerebrospinal fluid in a swine model of traumatic brain injury

Cytokine

Volumn 54, Issue 1, 2011, Pages 20-23

  Solomon, Daniel ^a,b   Kim, Bobby ^a   Scultetus, Anke ^a,c   Arnaud, Francoise ^a   Auker, Charles ^a,c   Freilich, Daniel ^a   McCarron, Richard ^a,c  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Uniformed Serv Univ Hlth Sci   (United States)

Author keywords

Interleukin 1 ; Interleukin 10; RFVIIa; TBI; Tumor necrosis factor

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 1BETA; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EARLY INTERVENTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; IMMUNOGENICITY; IMMUNOMODULATION; INTRACRANIAL PRESSURE MONITORING; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN FUNCTION; SURVIVAL RATE; SWINE; TRAUMATIC BRAIN INJURY; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BRAIN INJURIES; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR VIIA; FEMALE; INTERLEUKIN-10; INTERLEUKIN-1BETA; MALE; RECOMBINANT PROTEINS; SWINE; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; SUIDAE;

EID: 79952071104     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.12.013     Document Type: Article

References (18)

1. Spinella P.C., Perkins J.G., McLaughlin D.F., Niles S.E., Grathwohl K.W., Beekley A.C., et al. The effect of recombinant activated factor VII on mortality in combat-related casualties with severe trauma and massive transfusion. J Trauma 2008, 64(2):286-293. [discussion 284-93].
2. Dutton R.P., McCunn M., Hyder M., D'Angelo M., O'Connor J., Hess J.R., et al. Factor VIIa for correction of traumatic coagulopathy. J Trauma 2004, 57(4):709-718. [discussion 709-18].
3. Zaaroor M., Soustiel J.F., Brenner B., Bar-Lavie Y., Martinowitz U., Levi L. Administration off label of recombinant factor-VIIa (rFVIIa) to patients with blunt or penetrating brain injury without coagulopathy. Acta Neurochir (Wien) 2008, 150(7):663-668.
4. Stein D.M., Dutton R.P., Kramer M.E., Handley C., Scalea T.M. Recombinant factor VIIa: decreasing time to intervention in coagulopathic patients with severe traumatic brain injury. J Trauma 2008, 64(3):620-627. [discussion 627-28].
5. Zhang J, Groff RFT, Chen XH, Browne KD, Huang J, Schwartz ED, et al. Hemostatic and neuroprotective effects of human recombinant activated factor VII therapy after traumatic brain injury in pigs. Exp Neurol 2008;210(2):645-55.
6. Piek J., Chesnut R.M., Marshall L.F., van Berkum-Clark M., Klauber M.R., Blunt B.A., et al. Extracranial complications of severe head injury. J Neurosurg 1992, 77(6):901-907.
7. Muth H., Kreis I., Zimmermann R., Tillmanns H., Holschermann H. Differential gene expression in activated monocyte-derived macrophages following binding of factor VIIa to tissue factor. Thromb Haemost 2005, 94(5):1028-1034.
8. Sauaia A., Moore F.A., Moore E.E., Moser K.S., Brennan R., Read R.A., et al. Epidemiology of trauma deaths: a reassessment. J Trauma 1995, 38(2):185-193.
9. Mayer S, Brun N, Begtrup K, Broderick J, Davis S, Diringer M, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Eng J Med 2008;358(20):2127-37.
10. Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossaint R, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005;59(1):8-15 [discussion 15-18].
11. de Jonge E., Friederich P.W., Vlasuk G.P., Rote W.E., Vroom M.B., Levi M., et al. Activation of coagulation by administration of recombinant factor VIIa elicits interleukin 6 (IL-6) and IL-8 release in healthy human subjects. Clin Diagn Lab Immunol 2003, 10(3):495-497.
12. de Pont A.C., Moons A.H., de Jonge E., Meijers J.C., Vlasuk G.P., Rote W.E., et al. Recombinant nematode anticoagulant protein c2, an inhibitor of tissue factor/factor VIIa, attenuates coagulation and the interleukin-10 response in human endotoxemia. J Thromb Haemost 2004, 2(1):65-70.
13. Meisel C., Schwab J.M., Prass K., Meisel A., Dirnagl U. Central nervous system injury-induced immune deficiency syndrome. Nat Rev Neurosci 2005, 6(10):775-786.
14. Morganti-Kossmann M.C., Rancan M., Stahel P.F., Kossmann T. Inflammatory response in acute traumatic brain injury: a double-edged sword. Curr Opin Crit Care 2002, 8(2):101-105.
15. Knoblach S.M., Faden A.I. Interleukin-10 improves outcome and alters proinflammatory cytokine expression after experimental traumatic brain injury. Exp Neurol 1998, 153(1):143-151.
16. Bell M.J., Kochanek P.M., Doughty L.A., Carcillo J.A., Adelson P.D., Clark R.S., et al. Interleukin-6 and interleukin-10 in cerebrospinal fluid after severe traumatic brain injury in children. J Neurotrauma 1997, 14(7):451-457.
17. Vitarbo EA, Chatzipanteli K, Kinoshita K, Truettner JS, Alonso OF, Dietrich WD. Tumor necrosis factor alpha expression and protein levels after fluid percussion injury in rats: the effect of injury severity and brain temperature. Neurosurgery 2004;55(2):416-24 [discussion 415-24].
18. Kamm K., Vanderkolk W., Lawrence C., Jonker M., Davis A.T. The effect of traumatic brain injury upon the concentration and expression of interleukin-1beta and interleukin-10 in the rat. J Trauma 2006, 60(1):152-157.